Opiant Pharmaceuticals, Inc. (OPNT) |
| 20.65 0 (0%) 03-01 16:00 |
| Open: | 20.8765 |
| High: | 20.94 |
| Low: | 20.56 |
| Volume: | 562,778 |
| Market Cap: | 109(M) |
| PE Ratio: | -3.16 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 23.32 |
| Resistance 1: | 19.26 |
| Pivot price: | 16.42 |
| Support 1: | 12.68 |
| Support 2: | 10.55 |
| 52w High: | 27.36 |
| 52w Low: | 7.34 |
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.
| EPS | -0.310 |
| Book Value | 12.260 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.898 |
| Profit Margin (%) | -1.44 |
| Operating Margin (%) | 3.61 |
| Return on Assets (ttm) | 0.5 |
| Return on Equity (ttm) | -2.4 |
Thu, 02 Mar 2023
Opiant Pharmaceuticals Inc. (OPNT) Share Price Today | Opiant Pharmaceuticals (OPNT) Live NSE/BSE - Value Research
Thu, 02 Mar 2023
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. - PR Newswire
Fri, 13 Jan 2023
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In (NASDAQ:OPNT) - Seeking Alpha
Tue, 06 Dec 2022
U.S. FDA to review Emergent's OTC opioid overdose drug on priority - Reuters
Mon, 14 Nov 2022
Watkins Advises Opiant Pharmaceuticals in Sale to Indivior PLC - Latham & Watkins LLP
Wed, 08 Jun 2022
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |